公开(公告)号：US20240316142A1

公开(公告)日：2024-09-26

申请号：US18680542

申请日：2024-05-31

Applicant: Ferring B.V.

Inventor： Tine Kold Olesen ,  Bo-Eric Persson ,  Per Cantor ,  Egbert A. van der Meulen ,  Jens-Kristian Slott Jensen

IPC: A61K38/09 ,  A61K9/00 ,  A61K38/08

CPC classification number: A61K38/09 ,  A61K9/0019 ,  A61K38/08

Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

公开(公告)号：US20240131023A1

公开(公告)日：2024-04-25

申请号：US18460063

申请日：2023-09-01

Applicant: Arvinas Operations, Inc.

Inventor： LAWRENCE B. Snyder ,  Andrew P. Crew ,  Jing Wang ,  Hanqing Dong

IPC: A61K31/496 ,  A61K31/167 ,  A61K31/277 ,  A61K31/337 ,  A61K31/417 ,  A61K31/4523 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/57 ,  A61K31/661 ,  A61K31/663 ,  A61K31/675 ,  A61K38/09 ,  A61K47/54 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D498/10

CPC classification number: A61K31/496 ,  A61K31/167 ,  A61K31/277 ,  A61K31/337 ,  A61K31/417 ,  A61K31/4523 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/57 ,  A61K31/661 ,  A61K31/663 ,  A61K31/675 ,  A61K38/09 ,  A61K47/545 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D498/10

Abstract: This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

公开(公告)号：US11883498B2

公开(公告)日：2024-01-30

申请号：US17065737

申请日：2020-10-08

Applicant: PURDUE RESEARCH FOUNDATION

Inventor： Philip Stewart Low ,  Jyoti Roy

IPC: A61K47/65 ,  A61K45/06 ,  A61P35/00 ,  A61K38/09 ,  A61K47/54 ,  A61K49/00

CPC classification number: A61K47/545 ,  A61K38/09 ,  A61K45/06 ,  A61K47/65 ,  A61K49/0021 ,  A61P35/00

Abstract: The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally to method of making conjugates comprising an LHRH-R antagonist.

公开(公告)号：US20230355717A1

公开(公告)日：2023-11-09

申请号：US18136236

申请日：2023-04-18

Applicant: Rani Therapeutics, LLC

Inventor： Mir IMRAN

IPC: A61K38/22 ,  A61K9/00 ,  A61M25/10 ,  A61M5/00 ,  A61K9/48 ,  A61K38/09 ,  A61M37/00

CPC classification number: A61K38/22 ,  A61K9/0053 ,  A61M25/10 ,  A61M5/00 ,  A61K9/0009 ,  A61K9/0019 ,  A61K9/4891 ,  A61K38/09 ,  A61K9/0065 ,  A61M37/0015 ,  A61M31/002

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US20230285503A1

公开(公告)日：2023-09-14

申请号：US18122991

申请日：2023-03-17

Applicant: Antev Limited

Inventor： Finn Larsen ,  Francois Boutignon ,  Guy Poland

IPC: A61K38/09 ,  A61K9/00 ,  A61K9/19 ,  A61K47/12

CPC classification number: A61K38/09 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/12

Abstract: The present invention relates to a reconstitutable teverelix-TFA composition having a predefined molar ratio of teverelix to trifluoroacetate which is below the molar ratio required for microcrystal formation. Said composition remains stable during storage e.g., at a temperature around 2-8° C. Upon reconstitution a fixed amount of trifluoroacetate can be added to said composition thereby effectively and simply achieving an exact and desired molar ratio in order to obtain a fluid, milky microcrystalline aqueous teverelix-TFA suspension.

公开(公告)号：US20230263730A1

公开(公告)日：2023-08-24

申请号：US18170602

申请日：2023-02-17

Applicant: INVENTAGE LAB INC.

Inventor： Ju Hee KIM ,  Min Sung KIM

IPC: A61K9/16 ,  A61K38/09 ,  A61K9/00

CPC classification number: A61K9/1647 ,  A61K9/0019 ,  A61K38/09

Abstract: A composition for sustained-release injection comprising deslorelin, can prevent initial over-release by adjusting the release rate of deslorelin at a target site and can exhibit the effect of deslorelin for 1 month or more by being exposed in an amount enough to show the effect of deslorelin. Further, the microparticles can prepare microparticles that have a uniform particle size and are capable of exhibiting the effect of continuously releasing deslorelin for a long time.

公开(公告)号：US11717477B2

公开(公告)日：2023-08-08

申请号：US16963764

申请日：2019-04-10

Applicant: LiGalli B.V.

Inventor： Wilhelmus Nicolaas Gerardus Maria De Laat

IPC: A61K9/00 ,  A61K31/216 ,  A61K38/09 ,  A61K31/428 ,  A61K31/04 ,  A61K31/485 ,  A61K31/465 ,  A61K31/5513 ,  A61K38/28 ,  A61K38/24 ,  A61P15/08 ,  A61K9/08

CPC classification number: A61K9/0036 ,  A61K31/04 ,  A61K31/216 ,  A61K31/428 ,  A61K31/465 ,  A61K31/485 ,  A61K31/5513 ,  A61K38/09 ,  A61K38/24 ,  A61K38/28 ,  A61P15/08 ,  A61K9/08

Abstract: The present invention relates to a therapeutically active compound for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring. The present invention further relates to a therapeutically active compound selected from the group consisting of oxybutynin and other anti-muscarinic compounds, gonadotropin-releasing hormone (GnRH) and derivatives, both agonists and antagonists, nitroglycerin and other directly or indirectly acting cGMP enhancers, buprenorphine and other agonistic, antagonistic or partial (ant)agonistic opioids, nicotine and derivatives, lorazepam and other benzodiazepines, insulin and other blood glucose regulating compounds, FSH and other hormones for ovulation stimulation, pramipexol and other dopamine agonists, oxytocin and other hypothalamic peptides for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring.

公开(公告)号：US20190231881A1

公开(公告)日：2019-08-01

申请号：US16376028

申请日：2019-04-05

Applicant: Foresee Pharmaceuticals Co., Ltd.

Inventor： Yuhua LI ,  Benjamin CHIEN

IPC: A61K47/34 ,  A61K9/50 ,  A61K47/14 ,  A61K9/10 ,  A61K9/08 ,  A61K9/06 ,  A61K9/02 ,  A61K9/00 ,  A61K47/22 ,  A61K38/22 ,  A61K38/09

CPC classification number: A61K47/34 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0073 ,  A61K9/02 ,  A61K9/06 ,  A61K9/08 ,  A61K9/10 ,  A61K9/146 ,  A61K9/5031 ,  A61K38/09 ,  A61K38/2292 ,  A61K47/14 ,  A61K47/22

Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.

公开(公告)号：US20190192614A1

公开(公告)日：2019-06-27

申请号：US15886360

申请日：2018-02-01

Applicant: Ambiopharm, Inc.

Inventor： Juncai Bai ,  Simrat Singh

IPC: A61K38/09 ,  A61K9/19 ,  A61K9/16 ,  A61K47/32 ,  A61K47/10

CPC classification number: A61K38/09 ,  A61K9/1694 ,  A61K9/19 ,  A61K47/10 ,  A61K47/32 ,  A61P15/00

Abstract: Provided herein are, inter alia, a vial comprising lyophilized leuprolide and a method of manufacturing the same.

公开(公告)号：US20190183963A1

公开(公告)日：2019-06-20

申请号：US16042756

申请日：2018-07-23

Applicant: Thorn BioScience LLC

Inventor： James W. Lauderdale

IPC: A61K38/09 ,  A61K9/00 ,  A61K38/24 ,  A61K9/10 ,  A61D19/02 ,  A61K9/06 ,  A61K9/08

CPC classification number: A61K38/09 ,  A61D19/02 ,  A61K9/0019 ,  A61K9/0034 ,  A61K9/06 ,  A61K9/08 ,  A61K9/10 ,  A61K38/24

Abstract: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.